Coronavirus Spike Glycoprotein With Improved Expression and Stability
OwnerErica Ollman Saphire, Eduardo Olmedillas +1inventors
InventorsErica Ollman Saphire, Eduardo Olmedillas, Colin Mann
Life of this patent
Estimating the term…
Loading patent…
OwnerErica Ollman Saphire, Eduardo Olmedillas +1inventors
InventorsErica Ollman Saphire, Eduardo Olmedillas, Colin Mann
Estimating the term…
The present invention includes a mutant coronavirus spike protein, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an 51 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the resulting mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. In one example, the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Current SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e. B.1.621), and others.
A mutant coronavirus spike protein comprising at least one of the following modifications:
A method of making a mutant coronavirus spike protein comprising:
A method of immunizing a subject in need thereof against a coronavirus, the method comprising:
A nucleic acid sequence encoding a mutant coronavirus spike protein comprising:
A vector comprising a nucleic acid sequence encoding a mutant coronavirus spike protein comprising:
Dependencies are inferred from the claim text.